InvestSMART

Invex Therapeutics Ltd (ASX: IXC) - Announcements

- Current share price for IXC : $0.105

ASX company news and announcements for Invex Therapeutics Ltd (IXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Invex Therapeutics Ltd (IXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Invex Therapeutics Ltd (IXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Invex Therapeutics Ltd (IXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8 Final Director's Interest Notice 1 Jul 2024 8:22AM $0.060 $0.105 risen by 75%
$8 Notification of cessation of securities - IXC 26 Jun 2024 3:37PM $0.070 $0.105 risen by 50%
$8 Invex receives R&D Tax Rebate 21 Jun 2024 11:28AM $0.071 $0.105 risen by 47.89%
$8 Resignation of Dr Megan Baldwin 18 Jun 2024 10:06AM $0.072 $0.105 risen by 45.83%
$8 Details of Auditor Appointment/Resignation 19 Apr 2024 1:43PM $0.083 $0.105 risen by 26.51%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 12 Apr 2024 2:49PM $0.090 $0.105 risen by 16.67%
$8 Change of Director's Interest Notice 9 Apr 2024 1:16PM $0.084 $0.105 risen by 25%
$8 Notification of cessation of securities - IXC 8 Apr 2024 10:17AM $0.089 $0.105 risen by 17.98%
$8 Change of Director's Interest Notice 3 Apr 2024 11:16AM $0.087 $0.105 risen by 20.69%
$8 Amendment to Appendix 3A.4 22 Mar 2024 1:09PM $0.083 $0.105 risen by 26.51%
$8 ATO Class Ruling Return of Capital 20 Mar 2024 11:46AM $0.089 $0.105 risen by 17.98%
$8 Update on R&D Tax Rebate from UK Government 5 Mar 2024 10:26AM $0.079 $0.105 risen by 32.91%
$8 Appendix 4D and Half year report 16 Feb 2024 9:25AM $0.087 $0.105 risen by 20.69%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 11 Jan 2024 3:50PM $0.074 $0.105 risen by 41.89%
$8 Notification of cessation of securities - IXC 29 Dec 2023 3:52PM $0.081 $0.105 risen by 29.63%
$8 Invex and Peptron Mutually Terminate Manufacturing Agreement 22 Dec 2023 8:24AM $0.083 $0.105 risen by 26.51%
$8 Effective Date of Capital Return 5 Dec 2023 4:49PM $0.240 $0.105 fallen by 56.25%
$8 Results of Meeting 5 Dec 2023 4:40PM $0.240 $0.105 fallen by 56.25%
$8 Payment of Capital Return Proceeds 30 Nov 2023 3:55PM $0.230 $0.105 fallen by 54.35%
$8 Results of Meeting 28 Nov 2023 2:36PM $0.230 $0.105 fallen by 54.35%
$8 Chair's Address to Shareholders 28 Nov 2023 1:42PM $0.230 $0.105 fallen by 54.35%
$8 Change in substantial holding 28 Nov 2023 8:16AM $0.230 $0.105 fallen by 54.35%
$8 Change of Director's Interest Notice x 3 27 Nov 2023 8:08PM $0.230 $0.105 fallen by 54.35%
$8 Notification of cessation of securities - IXC 22 Nov 2023 1:08PM $0.235 $0.105 fallen by 55.32%
$8 Invex Granted European Patent for Exenatide in Hydrocephalus 22 Nov 2023 8:14AM $0.235 $0.105 fallen by 55.32%

51 - 75 of 296 results

Page 3 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.